Protecade 1 & 3,5 Mg 1 mg, 3,5 mg Powder for Solution for Injection
PDF Leaflet Revision Date: 27 June 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of multiple myeloma and mantle cell lymphoma.
Dosage (summary)
Administered twice a week, dose based on body surface area.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not established; avoid in pregnancy and breastfeeding.
Key Drug Interactions
- Ketoconazole
- Ritonavir
- Omeprazole
- Rifampicin
- Carbamazepine
- Phenytoin
- Phenobarbital
- St. John's Wort
Contraindications
- Hypersensitivity to bortezomib
- Severe lung or heart problems
Common side effects
- Nausea
- Vomiting
- Diarrhoea
- Fatigue
- Peripheral neuropathy
Counselling Points
- Monitor for signs of infection
- Regular blood tests required
- Avoid driving if experiencing dizziness
Serious warnings
- Serious allergic reactions
- Blood cell count reductions
- Tumour lysis syndrome
Important Disclaimer
The Protecade 1 & 3,5 Mg 1 mg, 3,5 mg Powder for Solution for Injection professional information leaflet below is the property of Adcock Ingram Critical Care and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
